Wire · opportunities
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 August 2026 · Fusion42 review
U.S. FDA granted accelerated approval for Ultragenyx's GENGLYCOS™, the first-ever gene therapy targeting glycogen storage disease type Ia (GSDIa), providing a treatment that reduces reliance on cornstarch and mitigates hypoglycemia risk.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 19 Aug 2026 and 1 Sep 2026.
◆ ◆ The Wire takeaway
You can now offer a transformative gene therapy to patients with GSDIa, bypassing the strict cornstarch regimen that shaped care for decades. This opens routes to engage providers who previously managed an untreatable ultra-rare disease.
◆ Coverage
4 sources · first reported 19 Aug 2026 · latest 1 Sep 2026
◆ Related on Wire
◆ Topics